Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Syros Pharmaceuticals

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

Syros Pharmaceuticals (NASDAQ:SYRS) brought in sales totaling $5.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 5.6%, resulting in a loss of $25.15 million.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Earnings Preview For Syros Pharmaceuticals

Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Syros Pharmaceuticals will report an earnings per share (EPS) of $-0.47.

Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Syros Pharmaceuticals (NASDAQ:SYRS) posted sales of $7.80 million. Earnings were up 8.51%, but Syros Pharmaceuticals still reported an overall loss of $23.81 million.

Recap: Syros Pharmaceuticals Q4 Earnings

Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Syros Pharmaceuticals's Earnings: A Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Syros Pharmaceuticals will report an earnings per share (EPS) of $-0.47.

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

European Medicines Agency

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prostate Cancer

Ulcerative Colitis

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play